Adipotide

What it is

Adipotide is a peptidomimetic, a lab-made molecule built to act like a peptide without being one in the strict sense. It joins two working parts together. The first, a short sequence called CKGGRAKDC, sticks to two proteins, prohibitin and annexin A2, found on the blood vessels that supply white fat tissue specifically. The second part, a sequence known as D-(KLAKLAK)2, disrupts the inner membrane of mitochondria once the molecule gets inside a cell, triggering that cell to die [1].

The overall strategy is to starve fat tissue of its blood supply rather than to change appetite, hormones, or how fat cells burn energy. Researchers first proved the underlying targeting idea using mice and a matching imaging probe, then tested the full apoptosis-triggering version in obese non-human primates [1][2]. A related version of the same targeting approach was also tested in a small early human cancer trial, which is where the kidney-safety signal that stopped the program first appeared.

How it is studied

The core primate work was done in obese rhesus macaques given daily injections under the skin for about a month, with body weight, body fat by imaging, blood insulin measures, and kidney tissue samples tracked before, during and after treatment, plus a recovery period after stopping [2]. A separate step-up study in the same primate model raised the amount given over about two months to see how much could be tolerated before kidney changes appeared. The original targeting concept was validated earlier using a matching imaging probe in mouse and human tissue samples [1].

What studies report

• In obese monkeys given daily injections for four weeks, researchers measured meaningful loss of body weight and abdominal fat, alongside improved insulin sensitivity. [2]
• Kidney tissue in the treated monkeys showed mild changes, larger at higher amounts given, in the proximal tubule, the part of the kidney that reabsorbs filtered fluid, and these changes reversed after the monkeys stopped receiving the compound. [2]
• The molecule's targeting piece, tested separately with an imaging probe, confirmed that it does concentrate specifically in the blood vessels of white fat tissue rather than acting throughout the body. [1]

What is not known

No completed human efficacy trial of Adipotide for weight loss exists; the human safety signal comes from a related targeting compound tested in a small, early-stage cancer study, not from Adipotide used for weight loss itself. It is not known whether the kidney changes seen in monkeys would appear, and at what amount, in people, or whether they would remain reversible with repeated or long-term use. Clinical development of the compound has not continued, so these questions have not been pursued further in humans.

Reported adverse findings

• Reversible injury to kidney tubule cells, worse at higher amounts given, was the main safety signal reported in obese primates in a step-up study that raised the amount over time. [2]

Regulatory status

No regulator, including the FDA and Health Canada, has approved Adipotide for any use. Clinical development toward a weight-loss indication has not proceeded past animal studies, and the compound remains an investigational research tool only.